A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis

Table 2 Ability of the MBDA score to differentiate between clinical remission and non-remission for different definitions of remission

Baseline MBDA score vs baseline remission criteria	AUROC	95% CI
DAS28-ESR (N = 140)	0.75	0.67–0.83
DAS28-CRP (N = 136)	0.69	0.60–0.78
SDAI (N = 135)	0.70	0.61–0.79
CDAI (N = 144)	0.68	0.59–0.77
ACR/EULAR Boolean (N = 136)	0.70	0.60–0.79
Baseline MBDA score vs IR/SR criteria	AUROC	95% CI
DAS28-ESR (N = 144)	0.73	0.61–0.85
DAS28-CRP (N = 144)	0.74	0.64–0.83
SDAI (N = 144)	0.71	0.62–0.80
CDAI (N = 145)	0.69	0.60–0.78
ACR/EULAR Boolean (N = 144)	0.65	0.56–0.74
tiMBDA score vs IR/SR criteria	AUROC	95% CI
DAS28-ESR (N = 147)	0.79	0.70–0.91
DAS28-CRP (N = 147)	0.79	0.70–0.88
SDAI (N = 147)	0.73	0.64–0.82
CDAI (N = 148)	0.71	0.62–0.80
ACR/EULAR Boolean (N = 147)	0.65	0.56–0.75

Area under the receiver operating curves (AUROCs) for the discriminative ability of the MBDA score. The upper section shows the ability of baseline MBDA score to differentiate between baseline clinical remission and no remission at baseline. The middle and lower sections show the ability of baseline MBDA score and the time-integrated MBDA (tiMBDA) score over 6 months, respectively, to differentiate between clinical intermittent or sustained remission (IR/SR) and sustained non-remission over 1 year

ISSN: 1478-6362